{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Acumen Pharmaceuticals, Inc.
Is Acumen Pharmaceuticals, Inc. overvalued or undervalued?
As of August 16, 2021, Acumen Pharmaceuticals, Inc. is considered overvalued with a significant downgrade in its valuation outlook, reflected by a negative Return on Equity of -75.93% and poor performance compared to peers and the S&P 500.
Is Acumen Pharmaceuticals, Inc. technically bullish or bearish?
As of June 3, 2025, Acumen Pharmaceuticals, Inc. is in a mildly bearish trend, with daily moving averages and monthly indicators signaling bearishness, despite some mildly bullish weekly signals.
What does Acumen Pharmaceuticals, Inc. do?
Acumen Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $29 million and a market cap of $73.90 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a return on equity of -75.93%.
How big is Acumen Pharmaceuticals, Inc.?
As of Jun 18, Acumen Pharmaceuticals, Inc. has a market capitalization of 73.90 million and reported net sales of 0.00 million with a net profit of -116.26 million for the latest four quarters. As of Dec 24, the company's shareholder's funds were 181.82 million, and total assets amounted to 238.99 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
